olivLaw · US equity research
Celldex Therapeutics, Inc. CLDX
In Vitro & In Vivo Diagnostic Substances · SIC 2835 · Vertical: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibodies for mast cell driven diseases such as chronic spontaneous urticaria. For a company still in development, the Phase 3 barzolvolimab program, with topline data expected in the fall, is the main factor that could change its risk profile, while the net loss in the second quarter of 2026 was 73.5 million USD.
At the close of 04 Nov 2026, Celldex Therapeutics, Inc. (CLDX) stock was 29.93 USD (+0.74% on the day), with market capitalisation 2.4 bn USD, beta 1.18, 52-week range 22.58–44.87 USD. Latest reported quarter (Q2 2026): revenue of 22.0 k USD (−97.0% YoY), net income of -73.5 m USD, diluted EPS -0.94 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 45.9
- neutral
- Bollinger (20, 2)
- 27.88 – 30.79
- in the upper half of the band · %B 0.70 · band width 9.9%
- SMA 50 / 200
- 33.39 / 32.71
- mixed trend
- MACD (12, 26, 9)
- -0.87 / -1.23
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −8.2% | −1.1% | −7.1 pp | — |
| 3 months | −27.1% | −0.5% | −26.7 pp | — |
| 6 months | −13.0% | +4.4% | −17.4 pp | — |
| Year to date | +10.2% | +12.3% | −2.1 pp | — |
| 1 year | +25.5% | +13.5% | +11.9 pp | −26.8% |
| 3 years | +15.2% | +76.4% | −61.2 pp | −63.5% |
| 5 years | −34.8% | +63.7% | −98.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.2 m | 1.2 m | 695.0 k | 730.0 k | 0 ≈ | 121.0 k | 15.0 k | 22.0 k |
| Research & development | 45.3 m | 46.9 m | 52.6 m | 54.2 m | 62.9 m | 75.3 m | 73.0 m | 67.5 m |
| Operating income | -52.1 m | -56.0 m | -62.7 m | -63.9 m | -73.6 m | -87.2 m | -84.4 m | -80.6 m |
| Depreciation & amortisation | 786.0 k ≈ | 819.0 k | 867.0 k | 873.0 k ≈ | 824.0 k ≈ | 816.0 k | 854.0 k | 902.0 k ≈ |
| Net income | -42.1 m | -47.1 m | -53.8 m | -56.6 m | -67.0 m | -81.3 m | -78.7 m | -73.5 m |
| Diluted EPS | -0.64 | -0.18 ≈ | -0.81 | -0.85 | -1.01 | -0.31 ≈ | -1.18 | -0.94 |
| Operating cash flow | -55.3 m ≈ | -32.5 m | -54.4 m | -44.0 m ≈ | -48.6 m ≈ | -63.9 m | -65.6 m | -57.4 m ≈ |
| Capex | 545.0 k ≈ | 756.0 k | 265.0 k | 728.0 k ≈ | 440.0 k ≈ | 1.3 m | 1.6 m | 3.2 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.5 m | 3.6 m | 7.4 m | 4.7 m | 2.4 m | 6.9 m | 7.0 m | 1.5 m |
| Revenue YoY | −25.2% | −62.5% | +107.6% | −37.3% | −49.3% | +192.0% | +2.0% | −78.0% |
| Net income | unavailable | unavailable | unavailable | unavailable | unavailable | -141.4 m | -157.9 m | -258.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -3.51 | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.90 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | -2,054.8% | -2,248.8% | -16,748.0% |
| Free cash flow | -76.0 m | -47.1 m | -42.0 m | -62.2 m | -105.6 m | -109.1 m | -159.7 m | -213.7 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 28.9 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 527.2 m USD
- Total assets
- 583.0 m USD
- Debt / equity
- unavailable
- Current ratio
- 10.49x
- ROE
- -40.6%
- ROA
- -37.6%
- FCF margin
- -13,829.1%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 7.4 m | 4.7 m | 2.4 m | 6.9 m | 7.0 m | 1.5 m | SEC (XBRL)· 25 Feb 2026verified |
| Cost of revenue | 200.0 k | 100.0 k | 100.0 k | 300.0 k | 200.0 k | 200.0 k | SEC (XBRL)· 25 Feb 2026verified |
| Gross profit | 7.2 m ≈ | 4.6 m ≈ | 2.3 m ≈ | 6.6 m ≈ | 6.8 m ≈ | 1.3 m ≈ | SEC (XBRL)· 25 Feb 2026derived |
| Research & development | 42.5 m | 53.3 m | 82.3 m | 118.0 m | 163.6 m | 245.1 m | SEC (XBRL)· 25 Feb 2026verified |
| Operating income | -63.4 m | -71.2 m | -115.2 m | -154.5 m | -195.1 m | -287.4 m | SEC (XBRL)· 25 Feb 2026verified |
| Depreciation & amortisation | 3.9 m | 3.1 m | 2.9 m | 3.0 m | 3.2 m | 3.4 m | SEC (XBRL)· 25 Feb 2026verified |
| EBITDA | -59.4 m ≈ | -68.2 m ≈ | -112.3 m ≈ | -151.5 m ≈ | -191.9 m ≈ | -284.0 m ≈ | SEC (XBRL)· 25 Feb 2026derived |
| Pre-tax income | -60.9 m | -70.7 m | -112.3 m | -141.4 m | -157.9 m | -258.8 m | SEC (XBRL)· 25 Feb 2026verified |
| Income tax | -1.2 m | -227.0 k | — | 0 | 0 | 0 | SEC (XBRL)· 25 Feb 2026verified |
| Net income | — | — | — | -141.4 m | -157.9 m | -258.8 m | SEC (XBRL)· 25 Feb 2026verified |
| Diluted EPS | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.90 | SEC (XBRL)· 25 Feb 2026verified |
| Weighted average diluted shares | 29.6 k | 42.9 k | 46.9 k | 48.4 m | 64.4 m | 66.4 m | SEC (XBRL)· 25 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 43.8 m | 39.1 m | 29.4 m | 34.8 m | 28.4 m | 28.9 m | SEC (XBRL)· 25 Feb 2026verified |
| Current assets | 197.8 m | 410.8 m | 317.7 m | 431.7 m | 747.2 m | 534.7 m | SEC (XBRL)· 25 Feb 2026verified |
| Property, plant & equipment, net | 3.8 m | 3.6 m | 3.7 m | 4.1 m | 4.3 m | 5.3 m | SEC (XBRL)· 25 Feb 2026verified |
| Intangibles (excl. goodwill) | 30.7 m | 27.2 m | 27.2 m | 27.2 m | 27.2 m | 27.2 m | SEC (XBRL)· 25 Feb 2026verified |
| Total assets | 235.8 m | 444.7 m | 352.7 m | 465.6 m | 792.3 m | 583.0 m | SEC (XBRL)· 25 Feb 2026verified |
| Accounts payable | 1.0 m | 1.2 m | 3.3 m | 3.5 m | 3.3 m | 1.2 m | SEC (XBRL)· 25 Feb 2026verified |
| Current liabilities | 14.2 m | 16.5 m | 18.6 m | 31.1 m | 39.5 m | 51.0 m | SEC (XBRL)· 25 Feb 2026verified |
| Total liabilities | 26.5 m | 25.2 m | 26.5 m | 36.5 m | 45.3 m | 55.8 m | SEC (XBRL)· 25 Feb 2026verified |
| Equity | 209.4 m † | 419.5 m † | 326.2 m † | 429.2 m † | 747.0 m † | 527.2 m † | SEC (XBRL)· 25 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -40.4 m | -60.9 m | -103.7 m | -107.3 m | -157.8 m | -210.9 m | SEC (XBRL)· 25 Feb 2026verified |
| Capex | 1.6 m | 1.2 m | 1.8 m | 1.8 m | 1.9 m | 2.7 m | SEC (XBRL)· 25 Feb 2026verified |
| Free cash flow | -42.0 m ≈ | -62.2 m ≈ | -105.6 m ≈ | -109.1 m ≈ | -159.7 m ≈ | -213.7 m ≈ | SEC (XBRL)· 25 Feb 2026derived |
| Investing cash flow | -98.2 m | -216.2 m | 89.9 m | -105.8 m | -290.1 m | 209.1 m | SEC (XBRL)· 25 Feb 2026verified |
| Financing cash flow | 171.2 m | 272.4 m | 4.1 m | 218.5 m | 441.4 m | 2.4 m | SEC (XBRL)· 25 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 2.4 bn USD
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -190,220.9% | 0 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -13.1% | 0 (on a fixed band) | 31% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 11.8x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -10.3% | 0 (on a fixed band) | 31% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Celldex Therapeutics, Inc. (CLDX). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 1.5 m USD in 2025; YoY growth -78.0%; net margin -190,220.9%; ROE -43.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 11.8x
What contradicts it
- Net margin: -190,220.9%
- Revenue CAGR 3Y: -13.1%
- FCF yield: -10.3%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
In Vitro & In Vivo Diagnostic Substances (SIC 2835) · same industry (4-digit SIC) · compared with 17 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IDXXIdexx Laboratories Inc | 55.0 bn | 47.1 | 68.9% | 25.4% | +10.4% | −7% / +50% |
| LNTHLantheus Holdings, Inc. | 6.6 bn | 24.5 | 22.2% | 17.7% | +0.5% | +72% / +41% |
| NEOGNeogen Corporation | 2.7 bn | — | -2.7% | -6.3% | −2.7% | +108% / −27% |
| TRIBTrinity Biotech PLC | 2.4 bn | — | — | -51.6% | +8.3% | −80% / −91% |
| CLDXCelldex Therapeutics, Inc. | 2.4 bn | — | -43.9% | -190,220.9% | −78.0% | +25% / +15% |
| NTLAIntellia Therapeutics, Inc. | 1.7 bn | — | -6,424.8% | -672.2% | +16.9% | +37% / −58% |
| QDELQuidelortho Corp | 984.6 m | — | -19.3% | -14.2% | −1.9% | −48% / −79% |
| ACHVAchieve Life Sciences, Inc. | 718.3 m | — | -845.0% | — | unavailable | +43% / +21% |
| MYGNMyriad Genetics, Inc. | 575.8 m | — | -32.5% | -14.0% | −1.6% | −21% / −68% |
| TKNOAlpha Teknova, Inc. | 395.7 m | — | -24.2% | -38.4% | +7.4% | +57% / +261% |
| ICCCImmuCell Corporation | 94.2 m | 138.2 | 2.6% | 2.6% | +4.3% | +114% / +128% |
| IMDXInsight Molecular Diagnostics Inc. | 86.7 m | — | — | -2,955.6% | +115.6% | −57% / −30% |
| BMRABiomerica, Inc. | 8.0 m | — | -113.8% | -115.5% | −16.2% | −27% / −77% |
| CDIOCardio Diagnostics Holdings, Inc. | 4.9 m | — | -75.4% | -44,771.8% | −57.5% | −43% / −97% |
| QCLSQ/C Technologies, Inc. | 3.2 m | — | -155.0% | — | −5.3% | −89% / −100% |
| VNRXVolitionRx Limited | 2.8 m | — | — | -1,043.1% | +40.0% | −97% / −99% |
| VRAXVirax Biolabs Group Ltd | 695.1 k | — | -109.6% | -95,739.2% | −96.0% | −88% / −98% |
| NNNNAnbio Biotechnology | — | 25.0 | 27.0% | 74.1% | +5.6% | −84% / unavailable |
1- and 3-year price returns: for CLDX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibodies for mast cell driven diseases such as chronic spontaneous urticaria. For a company still in development, the Phase 3 barzolvolimab program, with topline data expected in the fall, is the main factor that could change its risk profile, while the net loss in the second quarter of 2026 was 73.5 million USD 3.
SWOT
Strengths
- Well documented antibody platform and extensive clinical data in urticaria.
- Strengthened financial position after the latest public offering.
- Large Phase 3 program with enrollment completed ahead of guidance.
Weaknesses
- No product revenue yet and losses continue.
- Heavy dependence on one main product.
- The prurigo nodularis failure limits expansion of indications.
Opportunities
- If Phase 3 data are favorable, a regulatory filing could follow.
- The bispecific platform could support new inflammatory indications.
- Long-term benefit could support positioning as a disease modifying therapy.
Threats
- Failure of Phase 3 studies could reduce the value of the whole portfolio.
- Competition from approved therapies could limit adoption.
- Shareholder dilution could increase if financing becomes necessary in the short term.
Risks
- Financing dependencehigh
The company could need additional capital if programs expand, and terms could be unfavorable.
- Clinical failurehigh
Phase 3 results could be negative, and the prurigo nodularis study shows this risk is real.
- Regulatory reviewmedium
Approval by regulators is a lengthy and uncertain process that could delay revenues.
- Kolltan milestone paymentmedium
The milestone payment linked to approval could be made in shares, causing substantial dilution.
- Competition and reimbursementmedium
Acceptance by physicians and payers could be limited even if the drug is approved.
Investment thesis
What would need to be true (bull case)
- If Phase 3 data confirm efficacy, the company could become a leader in disease modification for chronic spontaneous urticaria.
- Its cash position could allow funding of studies through 2028, reducing immediate capital risk.
- The bispecific platform could generate a second pipeline of candidates if Phase 1 data hold up.
What would break the thesis
- The discontinued prurigo nodularis study suggests the mast cell hypothesis may not apply to every targeted disease.
- Continued losses could require new share issuance, diluting shareholders.
- With no product revenue, the company depends entirely on study results and future approvals.
What to watch
- Topline data from Phase 3 chronic spontaneous urticaria studiesQ3-Q4 2026
- Data from the Phase 2 atopic dermatitis studylate 2026
- BLA submission for barzolvolimab2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Celldex Therapeutics, Inc. describes itself as a biopharmaceutical company dedicated to exploring mast cell biology and developing therapeutic antibodies that engage the human immune system or affect critical pathways in severe inflammatory, allergic and autoimmune diseases 1. The company has had no commercial revenues from drug sales and reported an accumulated deficit of 1.8 billion USD as of December 31, 2025 1. Its declared strategy is to become a fully integrated commercial-stage company, either retaining full economic rights or pursuing advantageous partnerships 1. The operating loss was 287.4 million USD in 2025 1, and cash, cash equivalents and marketable securities were 717.6 million USD at June 30, 2026 23.
The lead program is barzolvolimab, a monoclonal antibody that binds the KIT receptor and inhibits its activity, studied in chronic spontaneous urticaria, cold urticaria, symptomatic dermographism and atopic dermatitis 13. Enrollment is complete in the Phase 3 chronic spontaneous urticaria studies, with 1,939 patients enrolled, and topline data are expected in September or October 2026, with a possible BLA filing in 2027 23. The prurigo nodularis program was discontinued after it did not meet its primary and key secondary endpoints at Week 12 2.
Segments
Barzolvolimab (anti-KIT)
The largest research segment is the barzolvolimab program, which absorbed most research and development spending in 2025, while the company still has no product revenue 1.
Market context
Chronic spontaneous urticaria is one of the most frequent dermatologic diseases, and about 50% of patients achieve symptom control with antihistamines, while omalizumab helps roughly half of the remaining antihistamine refractory patients 1. The market remains open if barzolvolimab confirms benefit in Phase 3 studies, but revenues depend on regulatory approval and reimbursement 1.
The company stated in 2026 that its cash is sufficient to fund planned operations through 2028, which could reduce near-term financing pressure if Phase 3 data are favorable 3.
Trends
- Disease modification ambitionstailwind
Long-term results show angioedema improvement persisting off treatment, which could shift treatment goals from symptom control to disease modification 3.
- Setbacks in related indicationsheadwind
The prurigo nodularis failure suggests mast cells may not be the key driver in every targeted disease 2.
- Equity financingmixed
The company recently raised funds through a public offering, but dilution for shareholders could still occur if capital needs grow 13.
- Rising trial costsheadwind
Research and development expenses have risen with larger trials, which could widen losses before approval 23.
Competitive position
Competition includes existing urticaria therapies such as omalizumab and other biologics in development for mast cell driven diseases 1. The documents do not detail commercial competitors, so this assessment remains limited.
The company's stated advantage is its distinct KIT inhibition mechanism and long-term data, which will need to be compared with approved treatments after Phase 3 studies conclude 23.
- Omalizumab (existing therapy)
IgE inhibitor mentioned in the documents as treatment for antihistamine refractory patients.
- H1 antihistamines
First line treatment that controls symptoms in about half of patients.
- Other urticaria antibodies in development
The documents do not name these, but indicate an unmet need.
- Biologics for Th2 inflammation
Category targeted by the bispecific candidate, without specific products identified in the documents.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report22 Sept 2026Other events · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report15 Jul 2026Departure or appointment of officers · Financial statements and exhibits
- Current report26 Jun 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Proxy statement29 Apr 2026
- Current report02 Apr 2026Material agreement · Other events · Financial statements and exhibits
- Annual report25 Feb 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Celldex Therapeutics, Inc. · 25 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Celldex Therapeutics, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Celldex Therapeutics, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.